By SPC News Staff
The FDA approved a new indication for adalimumab (Humira, AbbVie) to treat noninfectious intermediate, posterior and panuveitis.
Adalimumab is now the first and only FDA-approved noncorticosteroid therapy available for adults with noninfectious intermediate, posterior and panuveitis. This approval marks its 10th approved indication in the United States for immune-mediated diseases.
Prior to this approval, ophthalmologists and rheumatologists had no FDA-approved treatment options